bivalirudin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
hirudin derivatives	385	128270-60-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: bivalirudin angiomax angiox hirulog	designed to bind to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition Molecular weight: 2180.32 Formula: C98H138N24O33 CLOGP: LIPINSKI: 3 HAC: 57 HDO: 28 TPSA: 901.57 ALOGS: -4.67 ROTB: 66

Molecule

Description

Molfile Inchi Smiles

Synonyms:

bivalirudin
angiomax
angiox
hirulog

designed to bind to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition

Molecular weight: 2180.32
Formula: C98H138N24O33
CLOGP:
LIPINSKI: 3
HAC: 57
HDO: 28
TPSA: 901.57
ALOGS: -4.67
ROTB: 66

Drug dosage:

Dose	Unit	Route
0.25	g	P

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	0.27 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	8.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.42 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 15, 2000	FDA	MEDICINES CO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coronary artery thrombosis	426.90	61.51	64	1633	1075	63486250
Thrombosis in device	285.74	61.51	52	1645	2938	63484387
Coagulation time abnormal	235.32	61.51	28	1669	59	63487266
Device occlusion	151.99	61.51	36	1661	7351	63479974
Retroperitoneal haemorrhage	132.30	61.51	27	1670	2770	63484555
Heparin-induced thrombocytopenia	129.92	61.51	29	1668	4553	63482772
Cardiac procedure complication	89.08	61.51	13	1684	177	63487148
Thrombosis	87.78	61.51	40	1657	64715	63422610
Coronary artery perforation	82.25	61.51	10	1687	27	63487298
Haemorrhage	71.21	61.51	34	1663	60988	63426337
Coronary artery dissection	69.43	61.51	13	1684	849	63486476
Coagulation time prolonged	68.57	61.51	14	1683	1434	63485891
Cardiac tamponade	66.37	61.51	17	1680	4758	63482567
Coronary artery occlusion	66.13	61.51	19	1678	8172	63479153
Procedural complication	64.18	61.51	17	1680	5422	63481903
Post procedural complication	63.86	61.51	22	1675	17052	63470273
Vascular stent thrombosis	61.63	61.51	12	1685	965	63486360

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Thrombosis in device	512.37	54.38	100	2258	3225	34951348
Coronary artery thrombosis	483.80	54.38	89	2269	2070	34952503
Coagulation time abnormal	356.92	54.38	48	2310	108	34954465
Thrombosis	146.01	54.38	70	2288	50388	34904185
Procedural complication	138.27	54.38	36	2322	4247	34950326
Heparin-induced thrombocytopenia	133.32	54.38	37	2321	5558	34949015
Vascular stent thrombosis	106.07	54.38	27	2331	2908	34951665
Device occlusion	88.80	54.38	28	2330	6517	34948056
Acute myocardial infarction	80.06	54.38	48	2310	53671	34900902
Haemorrhage	74.21	54.38	45	2313	51325	34903248
Haemorrhage intracranial	64.49	54.38	28	2330	15918	34938655
Coronary artery dissection	64.32	54.38	12	2346	297	34954276
Oesophageal ulcer haemorrhage	62.45	54.38	11	2347	195	34954378
Coagulation time prolonged	62.24	54.38	15	2343	1287	34953286
Kounis syndrome	61.53	54.38	17	2341	2501	34952072
Cardiac procedure complication	57.34	54.38	10	2348	167	34954406
Reperfusion injury	57.15	54.38	9	2349	77	34954496
Chest pain	56.39	54.38	55	2303	126707	34827866

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coronary artery thrombosis	660.74	50.97	116	3627	2990	79737655
Thrombosis in device	608.11	50.97	118	3625	5324	79735321
Coagulation time abnormal	441.13	50.97	58	3685	170	79740475
Heparin-induced thrombocytopenia	258.61	50.97	65	3678	9617	79731028
Thrombosis	183.84	50.97	86	3657	84014	79656631
Procedural complication	175.93	50.97	46	3697	7937	79732708
Vascular stent thrombosis	172.42	50.97	39	3704	3671	79736974
Device occlusion	162.31	50.97	47	3696	11819	79728826
Acute myocardial infarction	132.75	50.97	67	3676	76969	79663676
Coagulation time prolonged	114.68	50.97	26	3717	2469	79738176
Haemorrhage	108.51	50.97	62	3681	91056	79649589
Retroperitoneal haemorrhage	108.45	50.97	29	3714	5441	79735204
Coronary artery perforation	107.33	50.97	15	3728	77	79740568
Haemorrhage intracranial	93.79	50.97	38	3705	26155	79714490
Cardiac tamponade	93.31	50.97	29	3714	9247	79731398
Coronary artery dissection	92.61	50.97	19	3724	1125	79739520
Cardiac procedure complication	92.59	50.97	16	3727	370	79740275
Cardiac arrest	85.43	50.97	68	3675	172028	79568617
Ventricular fibrillation	83.31	50.97	37	3706	31889	79708756
Coronary artery occlusion	79.05	50.97	29	3714	15286	79725359
Electrocardiogram ST segment elevation	75.09	50.97	24	3719	8373	79732272
Pulmonary haemorrhage	72.76	50.97	27	3716	14690	79725955
Reperfusion injury	66.70	50.97	11	3732	190	79740455
Post procedural complication	66.63	50.97	29	3714	23800	79716845
Coagulation time shortened	65.21	50.97	12	3731	400	79740245
Cardiogenic shock	64.99	50.97	34	3709	41880	79698765
Chest pain	60.20	50.97	70	3673	282234	79458411
Oesophageal ulcer haemorrhage	54.42	50.97	11	3732	604	79740041
Hypotension	52.19	50.97	82	3661	440235	79300410
International normalised ratio increased	51.90	50.97	38	3705	84683	79655962
Cardio-respiratory arrest	51.89	50.97	42	3701	108468	79632177
Pharyngeal haemorrhage	51.31	50.97	12	3731	1304	79739341

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B01AE06	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Direct thrombin inhibitors
FDA MoA	N0000009963	Thrombin Inhibitors
FDA EPC	N0000175518	Direct Thrombin Inhibitor
MeSH PA	D000925	Anticoagulants
MeSH PA	D000991	Antithrombins
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D006401	Hematologic Agents
MeSH PA	D011480	Protease Inhibitors
MeSH PA	D015842	Serine Proteinase Inhibitors
FDA EPC	N0000175980	Anti-coagulant
CHEBI has role	CHEBI:50249	anticoagulants
CHEBI has role	CHEBI:65232	thrombin inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID
Percutaneous coronary intervention	indication	415070008
Unstable Angina Pectoris during PTCA	indication
Acute coronary syndrome	off-label use	394659003
Intracranial hemorrhage	contraindication	1386000
Bleeding	contraindication	131148009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.06	acidic
pKa2	3.51	acidic
pKa3	3.89	acidic
pKa4	4.04	acidic
pKa5	4.21	acidic
pKa6	4.49	acidic
pKa7	9.65	acidic
pKa8	11.93	acidic
pKa9	12.59	acidic
pKa10	12.84	acidic
pKa11	13.06	acidic
pKa12	13.08	acidic
pKa13	13.4	acidic
pKa14	13.64	acidic
pKa15	13.69	acidic
pKa16	13.81	acidic
pKa17	13.99	acidic
pKa18	10.75	Basic
pKa19	8.16	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Prothrombin	Enzyme	P00734	THRB_HUMAN	INHIBITOR	Ki	8.60		IUPHAR	CHEMBL

External reference:

ID	Source
4021268	VUID
N0000148708	NUI
D03136	KEGG_DRUG
285044	RXNORM
C0168273	UMLSCUI
CHEBI:59173	CHEBI
CHEMBL2103749	ChEMBL_ID
CHEMBL3989957	ChEMBL_ID
DB00006	DRUGBANK_ID
C074619	MESH_SUPPLEMENTAL_RECORD_UI
6470	IUPHAR_LIGAND_ID
7282	INN_ID
TN9BEX005G	UNII
16129704	PUBCHEM_CID
15879	MMSL
234768	MMSL
41019	MMSL
d04744	MMSL
129498009	SNOMEDCT_US
400610005	SNOMEDCT_US
4021268	VANDF
009031	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Bivalirudin in 0.9% Sodium Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	0338-9572	INJECTION	250 mg	INTRAVENOUS	NDA	25 sections
Bivalirudin in 0.9% Sodium Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	0338-9576	INJECTION	500 mg	INTRAVENOUS	NDA	25 sections
Bivalirudin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-8300	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	28 sections
Bivalirudin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-8300	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	28 sections
Bivalirudin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-8300	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	28 sections
Bivalirudin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-8300	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	28 sections
bivalirudin	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3158	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	250 mg	INTRAVENOUS	NDA authorized generic	25 sections
Angiomax	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3447	INJECTION	250 mg	INTRAVENOUS	NDA	25 sections
Angiomax	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3447	INJECTION	250 mg	INTRAVENOUS	NDA	25 sections
bivalirudin	HUMAN PRESCRIPTION DRUG LABEL	1	0781-9158	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	250 mg	INTRAVENOUS	NDA authorized generic	25 sections
Bivalirudin	HUMAN PRESCRIPTION DRUG LABEL	1	16729-275	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	25 sections
Bivalirudin	HUMAN PRESCRIPTION DRUG LABEL	1	42023-622	INJECTION, SOLUTION	250 mg	INTRAVENOUS	NDA	26 sections
Bivalirudin	HUMAN PRESCRIPTION DRUG LABEL	1	52958-034	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	23 sections
Bivalirudin	HUMAN PRESCRIPTION DRUG LABEL	1	55111-652	INJECTION	250 mg	INTRACAVERNOUS	ANDA	25 sections
BIVALIRUDIN	Human Prescription Drug Label	1	55150-210	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	25 sections
BIVALIRUDIN	Human Prescription Drug Label	1	55150-210	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	25 sections
BIVALIRUDIN	Human Prescription Drug Label	1	55150-210	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	25 sections
Bivalirudin	HUMAN PRESCRIPTION DRUG LABEL	1	63323-562	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	27 sections
Bivalirudin	HUMAN PRESCRIPTION DRUG LABEL	1	63323-562	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	27 sections
Bivalirudin	HUMAN PRESCRIPTION DRUG LABEL	1	67457-256	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	26 sections
bivalirudin	HUMAN PRESCRIPTION DRUG LABEL	1	70436-025	INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION	250 mg	INTRAVENOUS	ANDA	26 sections
Angiomax RTU	HUMAN PRESCRIPTION DRUG LABEL	1	70511-141	INJECTION, SOLUTION	250 mg	INTRAVENOUS	NDA	25 sections
Bivalirudin	HUMAN PRESCRIPTION DRUG LABEL	1	70860-402	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	26 sections
Bivalirudin RTU	HUMAN PRESCRIPTION DRUG LABEL	1	70860-403	INJECTION, SOLUTION	5 mg	INTRAVENOUS	NDA	26 sections
BIVALIRUDIN	HUMAN PRESCRIPTION DRUG LABEL	1	71288-427	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	26 sections
bivalirudin	HUMAN PRESCRIPTION DRUG LABEL	1	72572-035	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	250 mg	INTRAVENOUS	NDA authorized generic	25 sections